Artivion Receives FDA Approval for Nexus Aortic Arch System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy AORT?
Artivion announced that the FDA has approved the premarket approval application, or PMA, for the Nexus Aortic Arch System, developed by Endospan, Artivion's partner. The approval entitles Artivion to exercise its option to acquire Endospan at any time within 90 days of receiving this notice of FDA approval. Artivion has a $150M delayed draw term loan in place, secured in anticipation of this approval, to fund a potential acquisition. The company is working to complete its evaluation of the option following the earlier than anticipated approval. Nexus is a branched endovascular stent graft system approved in the U.S. for the minimally invasive treatment of aortic arch disease, including chronic aortic dissections. The FDA's approval is supported by data from the Nexus TRIOMPHE IDE trial, which demonstrated 90% patient survival from lesion-related death, 90% freedom from disabling stroke at 1-year post treatment, and 98% freedom from reintervention due to endoleaks at one year in a high-risk patient population.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AORT
Wall Street analysts forecast AORT stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 37.720
Low
40.00
Averages
51.71
High
58.00
Current: 37.720
Low
40.00
Averages
51.71
High
58.00
About AORT
Artivion, Inc. is engaged in manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The Company operates through two segments, which include Medical Devices and Preservation Services. The medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease, including heart valve disease, aortic aneurysms, and dissections, and, to a lesser extent, other conditions in cardiac and vascular surgery. It has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Artivion Shares Surge 5.3% on FDA Approval News
- Stock Price Surge: Artivion's shares rose 5.3% in the last trading session to close at $35.22, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's prospects.
- FDA Approval Impact: The FDA's premarket approval for the NEXUS Aortic Arch System allows Artivion to exercise its option to acquire its long-standing partner Endospan within 90 days of receiving this notice, further strengthening the company's market position.
- Earnings Expectations: Artivion is expected to report quarterly earnings of $0.06 per share, unchanged from the year-ago quarter, with revenues projected at $115.95 million, representing a 17.1% increase, indicating growth potential in the medical device sector.
- Market Trend Monitoring: Although the current EPS estimate has remained unchanged over the past 30 days, research shows that trends in earnings estimate revisions are closely correlated with short-term stock price movements, prompting investors to monitor Artivion's future performance closely.
See More
Artivion Receives FDA Approval for NEXUS Aortic Arch System
- FDA Approval Milestone: Artivion announced that its NEXUS Aortic Arch System has received premarket approval from the U.S. FDA, becoming the first branched endovascular stent graft cleared for use, offering a safer alternative to open-chest surgery and marking a significant advancement in the treatment of complex aortic arch disease.
- Clinical Data Support: The NEXUS TRIOMPHE IDE trial demonstrated that 90% of patients avoided lesion-related death, 90% were free from disabling stroke, and 98% avoided reintervention due to endoleaks one year post-treatment, highlighting the clinical value of this technology in a high-risk patient population.
- Global Market Expansion: The FDA approval allows Artivion to promote the NEXUS system in the U.S. market, further enhancing its influence in the global cardiovascular solutions sector while providing broader treatment options for American patients.
- Acquisition Opportunity: The FDA approval entitles Artivion to acquire Endospan Ltd. within 90 days, supported by a $150 million delayed draw term loan, reflecting the company's proactive strategy in investment and market expansion.
See More
Artivion Receives FDA Approval for NEXUS System
- FDA Approval: Artivion's NEXUS Aortic Arch System has received FDA approval, marking a significant advancement in the minimally invasive treatment of aortic arch disease, which is expected to enhance the company's competitiveness in this market.
- Acquisition Option: Following the FDA approval, Artivion has a 90-day window to exercise its option to acquire its partner Endospan, reflecting the company's proactive stance towards future growth opportunities that could strengthen its product portfolio.
- Funding Preparedness: Artivion has a $150 million delayed-draw term loan in place to support a potential acquisition, providing the company with financial flexibility to ensure it is not constrained during the acquisition process.
- Clinical Data Support: The FDA approval of the NEXUS system is backed by data from the NEXUS TRIOMPHE IDE trial, which demonstrated a 90% survival rate and a 98% freedom from reintervention in a high-risk patient population, further validating the product's clinical efficacy and market potential.
See More
Endospan's NEXUS Stent Graft System Receives FDA Approval
- FDA Approval Milestone: Endospan's NEXUS stent graft system has received premarket approval from the FDA, marking a significant advancement in the treatment options for aortic arch diseases, including chronic aortic dissections, which is expected to greatly enhance patient survival rates and treatment accessibility.
- Acquisition Option Activation: Artivion has the option to acquire Endospan within 90 days of FDA approval and has secured a $150 million delayed draw term loan, indicating the company's proactive financial strategy and readiness for potential integration.
- Clinical Data Validation: The NEXUS system demonstrated impressive outcomes in the TRIOMPHE IDE trial, with 90% patient survival at one year, 90% freedom from disabling stroke, and 98% freedom from reintervention due to endoleaks, underscoring its clinical efficacy in a high-risk patient population.
- Significant Market Potential: The introduction of the NEXUS system provides a new treatment avenue for patients with aortic arch disease, who have historically faced limited options, and with Artivion's presence in over 100 countries, this is expected to drive further global market expansion.
See More
Artivion to Participate in Oppenheimer Healthcare Conference
- Virtual Conference Participation: Artivion, Inc. will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference virtually on March 17, 2026, at 9:20 a.m. ET, showcasing its innovative solutions in cardiac and vascular surgery.
- Webcast Availability: The live chat will be accessible via Artivion's website on the Investors page, with an archived version available for 90 days post-event, ensuring that investors and stakeholders can access relevant information at their convenience.
- Company Background: Headquartered in Atlanta, Georgia, Artivion focuses on developing medical devices that address aortic diseases, with a product range that includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular tissues, marketed in over 100 countries.
- Diverse Product Portfolio: Artivion's offerings consist of four major product categories aimed at providing simple and elegant solutions for cardiac and vascular surgeons to tackle significant challenges in treating aortic diseases, thereby strengthening its competitive position in the global market.
See More
Artivion Reports Strong 2025 Earnings, Outlook for Growth in 2026
- Significant Revenue Growth: Artivion reported total adjusted revenues of $443.6 million for 2025, reflecting a 13% year-over-year increase, with Q4 revenue reaching $118.3 million, up 18.5% from 2024, indicating strong market performance and sustained customer demand.
- Substantial EBITDA Improvement: The adjusted EBITDA for 2025 grew by 26% to $102.7 million, with an EBITDA margin of 20.2%, showcasing the company's significant progress in cost control and operational efficiency, thereby enhancing future profitability.
- Strong Product Line Performance: In Q4, stent graft revenues surged by 36% year-over-year, while On-X heart valve revenues increased by 24%, reflecting Artivion's expanding market share in key product areas, particularly driven by robust demand in both the U.S. and international markets.
- Clinical Data Supporting Future Growth: Positive clinical trial results for Artivion's AMDS and NEXUS product lines are expected to drive further growth in 2026, with the AMDS market opportunity projected at $150 million and NEXUS at $150 million, highlighting the company's strong potential in innovative medical technologies.
See More
Artivion Shares Surge 5.3% on FDA Approval News
- Stock Price Surge: Artivion's shares rose 5.3% in the last trading session to close at $35.22, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's prospects.
- FDA Approval Impact: The FDA's premarket approval for the NEXUS Aortic Arch System allows Artivion to exercise its option to acquire its long-standing partner Endospan within 90 days of receiving this notice, further strengthening the company's market position.
- Earnings Expectations: Artivion is expected to report quarterly earnings of $0.06 per share, unchanged from the year-ago quarter, with revenues projected at $115.95 million, representing a 17.1% increase, indicating growth potential in the medical device sector.
- Market Trend Monitoring: Although the current EPS estimate has remained unchanged over the past 30 days, research shows that trends in earnings estimate revisions are closely correlated with short-term stock price movements, prompting investors to monitor Artivion's future performance closely.
See More
Artivion Receives FDA Approval for NEXUS Aortic Arch System
- FDA Approval Milestone: Artivion announced that its NEXUS Aortic Arch System has received premarket approval from the U.S. FDA, becoming the first branched endovascular stent graft cleared for use, offering a safer alternative to open-chest surgery and marking a significant advancement in the treatment of complex aortic arch disease.
- Clinical Data Support: The NEXUS TRIOMPHE IDE trial demonstrated that 90% of patients avoided lesion-related death, 90% were free from disabling stroke, and 98% avoided reintervention due to endoleaks one year post-treatment, highlighting the clinical value of this technology in a high-risk patient population.
- Global Market Expansion: The FDA approval allows Artivion to promote the NEXUS system in the U.S. market, further enhancing its influence in the global cardiovascular solutions sector while providing broader treatment options for American patients.
- Acquisition Opportunity: The FDA approval entitles Artivion to acquire Endospan Ltd. within 90 days, supported by a $150 million delayed draw term loan, reflecting the company's proactive strategy in investment and market expansion.
See More
Artivion Receives FDA Approval for NEXUS System
- FDA Approval: Artivion's NEXUS Aortic Arch System has received FDA approval, marking a significant advancement in the minimally invasive treatment of aortic arch disease, which is expected to enhance the company's competitiveness in this market.
- Acquisition Option: Following the FDA approval, Artivion has a 90-day window to exercise its option to acquire its partner Endospan, reflecting the company's proactive stance towards future growth opportunities that could strengthen its product portfolio.
- Funding Preparedness: Artivion has a $150 million delayed-draw term loan in place to support a potential acquisition, providing the company with financial flexibility to ensure it is not constrained during the acquisition process.
- Clinical Data Support: The FDA approval of the NEXUS system is backed by data from the NEXUS TRIOMPHE IDE trial, which demonstrated a 90% survival rate and a 98% freedom from reintervention in a high-risk patient population, further validating the product's clinical efficacy and market potential.
See More
Endospan's NEXUS Stent Graft System Receives FDA Approval
- FDA Approval Milestone: Endospan's NEXUS stent graft system has received premarket approval from the FDA, marking a significant advancement in the treatment options for aortic arch diseases, including chronic aortic dissections, which is expected to greatly enhance patient survival rates and treatment accessibility.
- Acquisition Option Activation: Artivion has the option to acquire Endospan within 90 days of FDA approval and has secured a $150 million delayed draw term loan, indicating the company's proactive financial strategy and readiness for potential integration.
- Clinical Data Validation: The NEXUS system demonstrated impressive outcomes in the TRIOMPHE IDE trial, with 90% patient survival at one year, 90% freedom from disabling stroke, and 98% freedom from reintervention due to endoleaks, underscoring its clinical efficacy in a high-risk patient population.
- Significant Market Potential: The introduction of the NEXUS system provides a new treatment avenue for patients with aortic arch disease, who have historically faced limited options, and with Artivion's presence in over 100 countries, this is expected to drive further global market expansion.
See More
Artivion to Participate in Oppenheimer Healthcare Conference
- Virtual Conference Participation: Artivion, Inc. will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference virtually on March 17, 2026, at 9:20 a.m. ET, showcasing its innovative solutions in cardiac and vascular surgery.
- Webcast Availability: The live chat will be accessible via Artivion's website on the Investors page, with an archived version available for 90 days post-event, ensuring that investors and stakeholders can access relevant information at their convenience.
- Company Background: Headquartered in Atlanta, Georgia, Artivion focuses on developing medical devices that address aortic diseases, with a product range that includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular tissues, marketed in over 100 countries.
- Diverse Product Portfolio: Artivion's offerings consist of four major product categories aimed at providing simple and elegant solutions for cardiac and vascular surgeons to tackle significant challenges in treating aortic diseases, thereby strengthening its competitive position in the global market.
See More
Artivion Reports Strong 2025 Earnings, Outlook for Growth in 2026
- Significant Revenue Growth: Artivion reported total adjusted revenues of $443.6 million for 2025, reflecting a 13% year-over-year increase, with Q4 revenue reaching $118.3 million, up 18.5% from 2024, indicating strong market performance and sustained customer demand.
- Substantial EBITDA Improvement: The adjusted EBITDA for 2025 grew by 26% to $102.7 million, with an EBITDA margin of 20.2%, showcasing the company's significant progress in cost control and operational efficiency, thereby enhancing future profitability.
- Strong Product Line Performance: In Q4, stent graft revenues surged by 36% year-over-year, while On-X heart valve revenues increased by 24%, reflecting Artivion's expanding market share in key product areas, particularly driven by robust demand in both the U.S. and international markets.
- Clinical Data Supporting Future Growth: Positive clinical trial results for Artivion's AMDS and NEXUS product lines are expected to drive further growth in 2026, with the AMDS market opportunity projected at $150 million and NEXUS at $150 million, highlighting the company's strong potential in innovative medical technologies.
See More
